lomerizine has been researched along with Inflammation in 1 studies
lomerizine: used to treat migraines
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the potential of lomerizine for repurposing as a treatment for neuroinflammation, we investigated the effects of lomerizine on LPS-induced proinflammatory responses in BV2 microglial cells, Alzheimer's disease (AD) excitatory neurons differentiated from induced pluripotent stem cells (iPSCs), and in LPS-treated wild type mice." | 8.31 | Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β. ( Cho, J; Hoe, HS; Hwang, JW; Jang, GM; Jeong, YJ; Lee, HJ; Park, JH; Seo, J, 2023) |
| "To assess the potential of lomerizine for repurposing as a treatment for neuroinflammation, we investigated the effects of lomerizine on LPS-induced proinflammatory responses in BV2 microglial cells, Alzheimer's disease (AD) excitatory neurons differentiated from induced pluripotent stem cells (iPSCs), and in LPS-treated wild type mice." | 4.31 | Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β. ( Cho, J; Hoe, HS; Hwang, JW; Jang, GM; Jeong, YJ; Lee, HJ; Park, JH; Seo, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, JH | 1 |
| Hwang, JW | 1 |
| Lee, HJ | 1 |
| Jang, GM | 1 |
| Jeong, YJ | 1 |
| Cho, J | 1 |
| Seo, J | 1 |
| Hoe, HS | 1 |
1 other study available for lomerizine and Inflammation
| Article | Year |
|---|---|
Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β.
Topics: Alzheimer Disease; Animals; Cytokines; Dyrk Kinases; Glycogen Synthase Kinase 3; Inflammation; Lipop | 2023 |